Key points are not available for this paper at this time.
Background: This research was planned to disclose the clinical effect along with safety of programmed cell death protein 1/programmed death ligand-1 (PD-1/PD-L1) blockers in postoperative chemotherapy for advanced colorectal cancer.Material and Methods: From June 2019 to June 2021, 23 advanced colorectal cancer patients received apatinib treatment and 28 advanced colorectal cancer patients received PD-1 inhibitors in our hospital were included.The safety and clinical efficacy of 2 therapeutic regimens were compared.Results: Relative to apatinib group, the proportion of stable disease in patients accepting PD-1 blockers presented higher (P=0.010), the median progression-free survival (PFS) of patients accepting PD-1 blockers was longer (P=0.0209), the median PFS of patients with no liver metastasis who accepted PD-1 blockers presented longer (P0.05).Conclusion: PD-1/PD-L1 blockers possess certain clinical efficacy and tolerability in treating advanced colorectal cancer.
Liu et al. (Thu,) studied this question.